Stockscreener 앱 받기
1.21
2.02%
-0.03
시간 외 거래:
1.21
전일 마감가:
$1.24
열려 있는:
$1.24
하루 거래량:
28,695
Relative Volume:
0.18
시가총액:
$59.56M
수익:
$42,000
순이익/손실:
$-11.44M
주가수익비율:
-4.8555
EPS:
-0.2492
순현금흐름:
$-7.93M
1주 성능:
-4.33%
1개월 성능:
+8.48%
6개월 성능:
-48.95%
1년 성능:
-37.69%
1일 변동 폭
$1.21
$1.255
1주일 범위
$1.21
$1.28
52주 변동 폭
$0.91
$3.22
Entera Bio Ltd Stock (ENTX) Company Profile
명칭
Entera Bio Ltd
전화
972-2-532-7151
주소
KIRYAT HADASSAH, MINRAV BUILDING, JERUSALEM
Compare ENTX vs VRTX, REGN, ARGX, ALNY, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ENTX
Entera Bio Ltd
|
1.21 | 61.04M | 42,000 | -11.44M | -7.93M | -0.2492 |
VRTX
Vertex Pharmaceuticals Inc
|
435.92 | 110.28B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
634.42 | 66.98B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
808.61 | 50.15B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
295.50 | 39.71B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
154.89 | 32.22B | 742.00K | -1.37B | -1.07B | -7.0731 |
Entera Bio Ltd Stock (ENTX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2021-03-22 | 개시 | Aegis Capital | Buy |
Entera Bio Ltd 주식(ENTX)의 최신 뉴스
Entera Bio Ltd. (ENTX) Q1 2026 Earnings: Narrower-Than-Expected Loss Drives Strong Earnings BeatRevenue Estimate Trend - Newser
Entera Bio (ENTX) Q1 2026 Earnings: Narrowing Losses as Cash Burn Remains in FocusCommunity Buy Alerts - Newser
Entera Bio (ENTX) Faces Selling Pressure as Stock Dips Below Key ResistancePrice Action Signals - Newser
[EFFECT] Entera Bio Ltd. SEC Filing - Stock Titan
Entera Bio (NASDAQ: ENTX) registers 19.6M shares; $14.5M possible on warrant exercises - Stock Titan
Entera Bio Ltd.Ordinary Shares (NQ: ENTX - FinancialContent
Entera Bio (ENTX) shareholder vote set for July 14, 2026; 2.5M-share plan increase - Stock Titan
TradingKey - TradingKey
Number of shareholders of Entera Bio Ltd. – HAM:5DT - TradingView
MSN Money - MSN
Entera Bio Sees Funding Sufficient Through 1Q27 >ENTX - Moomoo
Entera Bio Highlights Q1 2026 Progress and Financing - TipRanks
Entera Bio (ENTX) grants COO 72,993 RSUs in lieu of cash bonus - Stock Titan
Entera Bio (ENTX) CFO receives 58,394 RSUs through A2Z Counseling Ltd. - Stock Titan
Entera Bio (ENTX) awards 87,591 RSUs to Chief of R&D Burshtein - Stock Titan
Entera Bio Ltd. (NASDAQ: ENTX) registers 19.6M shares for resale under S-3 - Stock Titan
Entera Bio Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
Entera Bio (ENTX) widens Q1 loss as R&D doubles and cash runway nears Q1 2027 - Stock Titan
Entera pushes an osteoporosis pill toward Phase 3 as cash hits $20.4M - Stock Titan
Entera Bio (NASDAQ: ENTX) details Q1 2026 loss and cash runway to 2027 - Stock Titan
Press Release: Entera Announces First Quarter 2026 Financial Results and Updates Across Its Oral Peptide Programs - Moomoo
How Entera Bio (ENTX) performance reflects its true potential (Smart Money Flows) 2026-05-06Verified Stock Signals - newser.com
Entera Bio (ENTX) upgraded to buy: Here's what you should know - MSN
Entera Bio (ENTX) to Release Earnings on Friday - MarketBeat
Entera Bio (ENTX) Upgraded to Buy: Here's What You Should Know - sharewise.com
HC Wainwright Has Strong Estimate for Entera Bio Q1 Earnings - MarketBeat
What is HC Wainwright's Estimate for Entera Bio Q1 Earnings? - MarketBeat
ENTX - Finviz
HC Wainwright Has Lowered Expectations for Entera Bio (NASDAQ:ENTX) Stock Price - MarketBeat
H.C. Wainwright lowers Entera Bio stock price target on dilution By Investing.com - Investing.com South Africa
Entera Bio Price Target Cut to $9.00/Share From $10.00 by HC Wainwright & Co. - Moomoo
H.C. Wainwright lowers Entera Bio stock price target on dilution - Investing.com
Entera Bio Touts EB613 Oral Anabolic Tablet as Osteoporosis Care Gap Persists, Phase III Near - MarketBeat
Leading Osteoporosis Experts Are Lining Up Behind Entera Bio (NASDAQ: ENTX) - TradingView
Articles from Entera Bio Ltd. - FinancialContent
ENTX (Entera Bio Ltd. Ordinary Shares) rises 4.42 percent on Q4 2025 EPS beat despite sharp year over year revenue decline.Post Announcement - Xã Thanh Hà
ENTX (Entera Bio Ltd. Ordinary Shares) Q4 2025 narrower than expected loss pushes shares 6.67 percent higher in daily trading.Trending Volume Leaders - Xã Thanh Hà
ENTX (Entera Bio Ltd. Ordinary Shares) tops Q4 2025 EPS estimates, shares climb nearly seven percent on upbeat investor reaction.Real Trader Insights - Cổng thông tin điện tử tỉnh Tây Ninh
ENTX: Oral anabolic EB613 could transform osteoporosis care by improving access and adherence - TradingView
ENTX: Oral anabolic EB613 could close major osteoporosis treatment gaps and improve patient outcomes - TradingView
BriefCast Publishes Transcript: Entera Bio's Osteoporosis KOL Roundtable on EB613Oral Anabolic Tablet Opportunity - Yahoo Finance
Entera Bio (ENTX) Stock: Institutional Signals (Technical Weakness) 2026-04-20Low Risk Entry - Cổng thông tin điện tử tỉnh Lào Cai
Entera Bio (ENTX) Stock: Worth Buying? (Investor Interest) 2026-04-18Fundamentals - Xã Châu Thành
Entera Bio Ltd (ENTX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Entera Bio Ltd 주식 (ENTX) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Ellis Sean | Director |
Mar 05 '26 |
Buy |
1.23 |
10,000 |
12,300 |
188,098 |
| Rubin Steven D | Director |
Feb 12 '26 |
Buy |
1.49 |
5,000 |
7,450 |
15,000 |
| Rubin Steven D | Director |
Feb 09 '26 |
Buy |
1.20 |
10,000 |
12,000 |
10,000 |
| Ellis Sean | Director |
Feb 09 '26 |
Buy |
1.24 |
18,000 |
22,320 |
178,098 |
| Toledano Miranda Jayne | Chief Executive Officer |
Dec 29 '25 |
Buy |
1.81 |
11,000 |
19,912 |
426,575 |
1.49%
0.12%
자본화:
|
볼륨(24시간):